Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
NICE has approved semaglutide 2.4 mg (Wegovy) for use within specialist weight management services (NICE TA875), subject to specific eligibility criteria including a BMI of 35 kg/m or above (or 32.5 kg/m or above in people from certain ethnic minority backgrounds at higher metabolic risk) alongside at least one weight-related comorbidity
The preference usually comes down to mechanism and outcome potential
Cohen G, Rubinstein S, Gur Y, Breitbart H
Semaglutide (Wegovy) was tested in clinical trials and was found to help people lose an average of 21% of their starting weight after 72 weeks on the 7.2mg maintenance dose
Dizziness may arise from rapid drops in blood pressure (orthostatic hypotension), dehydration due to reduced appetite and food intake, or changes in glucose metabolism if you are also taking diabetes medications
US$ 28.83
US$ 20.39
US$ 28.02
